Fresh off the heels of mega financing round, Germany's BioNTech makes $100M US IPO play

Natalie Grover

Reporter

Two months after one of the largest single private funding rounds for a biotech company in European history, German cancer drug developer BioNTech is gunning for a $100 million US IPO.

Helmut Jeggle

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Fresh off the heels of mega financing round, Germany's BioNTech makes $100M US IPO play

Natalie Grover

Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Fresh off the heels of mega fi­nanc­ing round, Ger­many's BioN­Tech makes $100M US IPO play

Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Fresh off the heels of mega financing round, Germany's BioNTech makes $100M US IPO play